Crossmark

Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management

Published Online: 2022-07-19

Published Print: 2022-09

Authors

Kaynak, Emine https://orcid.org/0000-0001-9850-2532
Clausen, Johannes
License Information

Text and Data Mining valid from 2022-07-19

Version of Record valid from 2022-07-19
More Information

Article History

Received: 5 March 2022

Accepted: 25 May 2022

First Online: 19 July 2022

Conflict of interest

: J. Clausen declares the following: Novartis: Lecture fees, consultancy fees; BMS: consultancy fees. E. Kaynak declares that she has no competing interests.

Document is current